Effect of Tinzaparin on Inflammatory Biomarkers During the Acute Phase of Deep Vein Thrombosis
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Anticoagulants influence either coagulation, inflammation and inflammatory processes in deep
vein thrombosis (DVT). Acute DVT cause an inflammatory response that may persist for a long
period of time. There is a need to describe patterns of change in serum biomarker levels
after acute DVT, and explore the association between trajectory biological patterns and
clinical evolution in the era of various anticoagulants in the acute phase of treatment in
order to be able to further avoid recurrence and late sequelae. It appears that direct oral
anticoagulants and heparin alter inflammatory markers in different ways. It is therefore
important to study the evolution of markers according to the different treatments used and
secondarily to compare them with each other. Tinzaparin is used in the long term in patients
with DVT, it is necessary to measure the evolution of inflammatory markers and then in
another study to compare with the other molecules.